StreetInsider.com News Articles

Daxor Corp. (DXR) PT Lowered to $18 at Lake Street

Tue, 01 Sep 2026 13:05:13 -0400

Lake Street analyst Frank Takkinen lowered the price target on Daxor Corp. (NASDAQ: DXR) to $18.00 (from $23.00) while maintaining a Buy rating.

Daxor reports 16% kit sales growth in first half of 2026

Tue, 01 Sep 2026 08:00:42 -0400

Daxor Corporation (Nasdaq: DXR) issued a shareholder letter from CEO and President Michael Feldschuh providing a financial and operational update for the six months ended June 30, 2026.

Unaudited kit sales grew 16% in the first half of 2026 compared with the prior-year period. The company completed a $9 million registered direct offering in January 2026, issuing 765,958 shares at $11.75 per share. As of June 30, 2026, net assets stood at $51,832,130, up from $45,887,266 at December 31, 2025. Net asset value per share was $8.88 at June 30, 2026, compared with $9.07 at December 31, 2025.

Daxor used a portion

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Tue, 01 Sep 2026 08:00:00 -0400

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.

Dear Valued Shareholders,

“It’s still Day 1.” — Jeff Bezos
That's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our clinical data, our acquisition of our supplier, Isotex Diagnostics, our capital raise

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Tue, 01 Sep 2026 08:00:00 -0400

Dear Valued Shareholders,

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA^™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor to exhibit blood volume analyzer at dysautonomia conference

Tue, 07 Jul 2026 08:03:06 -0400

Daxor Corporation (NASDAQ: DXR) announced it will exhibit for the first time at the 14th Annual Dysautonomia International Conference, scheduled for July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas.

The Oak Ridge, Tennessee-based company plans to display its FDA-cleared Blood Volume Analyzer (BVA), a lab-based diagnostic device designed to measure plasma and red blood cell volumes. The conference brings together physicians, researchers, clinicians, and patient advocates focused on autonomic disorders.

"For too long, dysautonomia patients have faced an uphill battle due to the limitations of traditional diagnostics," said John L. Jefferies, MD, MPH, MBA,

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Tue, 07 Jul 2026 08:00:00 -0400

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy

Oak Ridge, TN, July 07, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting for the first time at the 14th Annual Dysautonomia International Conference. Daxor will feature its FDA-cleared next-generation rapid, lightweight, lab-based Blood Volume Analyzer (BVA^™). The premier global event for autonomic disorders will take place from July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Tue, 07 Jul 2026 08:00:00 -0400

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Tue, 07 Jul 2026 08:00:00 -0400

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Tue, 07 Jul 2026 08:00:00 -0400

Daxor to Showcase How BVA Provides the Objective Plasma and Red Blood Cell Data Needed to Target Dysautonomia Therapy

Form 4 DAXOR CORP For: Jun 23 Filed by: Michel Robert J

Thu, 25 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260625/26693585.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Michel Robert J

Thu, 25 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260625/26693585.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Feldschuh Michael Richard

Thu, 25 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260625/26693542.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Feldschuh Michael Richard

Thu, 25 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260625/26693542.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Feldschuh Jonathan Adam

Thu, 25 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260625/26693526.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Feldschuh Jonathan Adam

Thu, 25 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260625/26693526.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Goudie Joy S.

Thu, 25 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260625/26693473.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Goudie Joy S.

Thu, 25 Jun 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260625/26693473.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Cremisi Henry D.

Thu, 25 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260625/26693436.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Cremisi Henry D.

Thu, 25 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260625/26693436.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Feuer Edward

Thu, 25 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260625/26693409.html

Form 4 DAXOR CORP For: Jun 23 Filed by: Feuer Edward

Thu, 25 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260625/26693409.html